A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy

Ghassan K. Abou-Alfa, et al.
ASCO Annual Meeting 2016, June 3-7, 2016, Chicago Illinois
Download the poster here
Poster Presentation